TipRanks on MSN10h
Moderna’s 2024 Struggles: Navigating Commercial Challenges and Market Competition in the Vaccine Industry
Moderna (MRNA) has disclosed a new risk, in the Sales & Marketing category. Moderna faces significant commercial challenges, particularly in ...
Moderna and Other Vaccine Stocks Climb Amid Concerns About Coronavirus Study in China
Concerns about coronavirus news out of China may have moved some vaccine-maker and travel stocks Friday.